Trial Profile

Phase 2 trial of CVL 865 to treat people living with epilepsy who do not respond to currently available therapies

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darigabat (Primary)
Indications Epilepsy
Focus Proof of concept; Therapeutic Use
Sponsors Cerevel Therapeutics

Most Recent Events

30 Jul 2020 According to a Cerevel Therapeutics media release, it plans to initiate the trial in the second half of 2020, with data expected in the second half of 2022
17 Apr 2019 New trial record
09 Apr 2019 According to a Cerevel Therapeutics media release, this trial is expected to begin by year-end.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com